Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing afterââ¥â1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial.
接受至少 1 线系统治疗后进展的复发/转移性头颈部鳞状细胞癌患者的总体生存率，采用新型的、首创的基于细胞封装的免疫疗法 MVX-ONCO-1 进行治疗：SAKK 11/16 IIa 期试验的结果
期刊:Experimental Hematology & Oncology
影响因子:13.5
doi:10.1186/s40164-025-00703-x
Fernandez Eugenio, Vernet Rémi, Urwyler Muriel, Von Rohr Olivier, Charrier Emily, Belkouch Marie-Claude, Saingier Valentin, Courtout Fabien, DeVito Claudio, Ancrenaz Virginie, Dulguerov Nicolas, Karenovics Wolfram, Grogg Julien, Renaux Jessica, Gobat Katrin, Müller Gisela, Brezina Tomas, Rordorf Tamara, Joerger Markus, Michielin Olivier, Villard Jean, Mach Nicolas
